GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of 18 months in and TRIUMPH is still the thing I get wrong — 31 comments in the full submission. View in context.
479
c/trialwatch·submitted 2 months ago by u/nhs_waitlist_n

18 months in and TRIUMPH is still the thing I get wrong

Statsbranch of 8 comments

Something I noticed reading old threads that I have not seen said out loud. The advice on TRIUMPH in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers with…

Read the full submission and all 31 comments →

This branch

8 comments, started 2 months ago
u/sanne_laurent7 points·2 months ago

SELECT reported a SURMOUNT hazard ratio but the absolute event rate is what changes clinical practice.

replysharereportpermalink
u/nhs_waitlist_nOPUK3 points·2 months ago

SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.

replysharereportpermalink
u/laila_almeida-31 points·2 months ago

Strongly agree. Phase 2 is investigational, not conclusive.

replysharereportpermalink
u/curious_panel_only8 points·2 months ago

event rates are more informative than hazard ratios alone

replysharereportpermalink
u/hub_opssite staff4 points·2 months ago

Yeah, absolute numbers matter more than the press release.

replysharereportpermalink
u/naomi_ekstrom4 points·2 months ago

That is net peptide content, not purity. Different number, different meaning.

replysharereportpermalink
u/yusuf_ramos2 points·2 months ago

Strongly agree. Phase 2 is investigational, not conclusive.

replysharereportpermalink
u/ahmed_iyer1 point·2 months ago

the relative risk reduction in headlines is not the whole story

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →